Literature DB >> 18347227

Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor?

Alexander W Krug1, Monika Ehrhart-Bornstein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18347227     DOI： 10.1161/HYPERTENSIONAHA.107.109439

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  26 in total

1.  Modified high-density lipoprotein modulates aldosterone release through scavenger receptors via extra cellular signal-regulated kinase and Janus kinase-dependent pathways.

Authors:  Sarama Saha; Juergen Graessler; Peter E H Schwarz; Claudia Goettsch; Stefan R Bornstein; Steffi Kopprasch
Journal:  Mol Cell Biochem       Date:  2012-03-01       Impact factor: 3.396

2.  Elevated mineralocorticoid receptor activity in aged rat vascular smooth muscle cells promotes a proinflammatory phenotype via extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase and epidermal growth factor receptor-dependent pathways.

Authors:  Alexander W Krug; Lena Allenhöfer; Robert Monticone; Gaia Spinetti; Michael Gekle; Mingyi Wang; Edward G Lakatta
Journal:  Hypertension       Date:  2010-04-26       Impact factor: 10.190

3.  Blood pressure response to angiotensin II is enhanced in obese Zucker rats and is attributed to an aldosterone-dependent mechanism.

Authors:  Helge Müller-Fielitz; Margot Lau; Olaf Jöhren; Florian Stellmacher; Markus Schwaninger; Walter Raasch
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

Review 4.  Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum.

Authors:  Rhonda M Cooper-DeHoff; Michael A Pacanowski; Carl J Pepine
Journal:  J Am Coll Cardiol       Date:  2009-02-03       Impact factor: 24.094

Review 5.  The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy.

Authors:  Atsuhisa Sato
Journal:  Hypertens Res       Date:  2015-03-12       Impact factor: 3.872

Review 6.  Interaction of aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease: a narrative review.

Authors:  Andrew S Bomback; Philip J Klemmer
Journal:  Am J Nephrol       Date:  2009-03-20       Impact factor: 3.754

Review 7.  Resistant hypertension in diabetes mellitus.

Authors:  George Bayliss; Larry A Weinrauch; John A D'Elia
Journal:  Curr Diab Rep       Date:  2014-08       Impact factor: 4.810

8.  Effect of low dose mineralocorticoid receptor antagonist eplerenone on glucose and lipid metabolism in healthy adult males.

Authors:  Alexander W Krug; Lissy Stelzner; Ajaykumar D Rao; Andrew H Lichtman; Gordon H Williams; Gail K Adler
Journal:  Metabolism       Date:  2012-09-21       Impact factor: 8.694

9.  Disordered aldosterone-volume relationship in end-stage kidney disease.

Authors:  Andrew S Bomback; Abhijit V Kshirsagar; Maria E Ferris; Philip J Klemmer
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2009-10-28       Impact factor: 1.636

10.  Canonical transient receptor potential channels expression is elevated in a porcine model of metabolic syndrome.

Authors:  Guoqing Hu; Elena A Oboukhova; Sanjay Kumar; Michael Sturek; Alexander G Obukhov
Journal:  Mol Endocrinol       Date:  2009-02-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.